Disease Landscape and Forecast Insights

A Survey of Rheumatologists and Interviews with Payers in the EU5 Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that…

Rheumatoid arthritis (RA) is a complex, chronic autoimmune condition that causes pain, stiffness, and swelling that, in moderate to severe cases, limits motion and functionality. The…

Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs? Nine biologics are approved to treat rheumatoid arthritis (RA),…

Last Updated 15 December 2014 Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…

Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that typically results in permanent, debilitating tissue damage. Biological…

Last Updated 15 December 2014 Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…

For the estimated 2.1 million people in the United States with rheumatoid arthritis (RA), there are multiple disease modifying anti-rheumatic drugs (DMARDs) available for reducing the signs and…

The Rheumatoid Arthritis (RA) treatment paradigm continues to evolve as new therapeutic options are added to physicians’ toolkits. The positioning of newer agents (e.g., Pfizer’s Xeljanz,…

The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…

TreatmentTrends®: Rheumatoid Arthritis 2014 (US) explores the use of conventional DMARDs as well as biologics or Xeljanz for the treatment of rheumatoid arthritis (RA). One hundred U.S…

The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary…

This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA). LaunchTrends…